GenfitAct. Aktie

3,40 EUR -0,10 EUR -2,86 %

10:30:40

STU

3,49 EUR ±0,00 EUR ±0,00 %

03.03.2025

PAR

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.173,78 Mio. EUR

Div. Rendite0,00%

WKNA0LGJ2

ISINFR0004163111

SymbolGNFTF

GenfitAct. Aktien News

Sortieren:Datum Meistgelesen

27.02.25GlobeNewswireGENFIT Announces Revenues and Cash Position as of December 31, 2024

21.02.25GlobeNewswireGENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders’ general meeting

14.02.25GlobeNewswireGENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders

WerbungGenfitAct.-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

10.02.25GlobeNewswireGENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders

06.02.25GlobeNewswireGENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025

30.01.25GlobeNewswireGENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan

29.01.25GlobeNewswireGENFIT Announces 2025 Financial Calendar

13.01.25GlobeNewswireGENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

13.11.24GlobeNewswireGENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

07.11.24GlobeNewswireGENFIT Reports Third Quarter 2024 Financial Information

23.09.24GlobeNewswireGENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

19.09.24GlobeNewswireGENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update

26.07.24GlobeNewswireGENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis

09.07.24GlobeNewswireGENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

17.06.24GlobeNewswireGENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH

10.06.24GlobeNewswireGENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis

29.05.24GlobeNewswireGENFIT to Present Latest ACLF Research at EASL Congress™ 2024

22.05.24GlobeNewswireGENFIT: May 22, 2024 Combined Shareholders Meeting Results

14.05.24GlobeNewswireGENFIT Reports First Quarter 2024 Financial Information

25.04.24GlobeNewswireGENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

15.04.24GlobeNewswireGENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

05.04.24GlobeNewswireGENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F

04.04.24GlobeNewswireGENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

29.02.24GlobeNewswireGENFIT Announces Revenues and Cash Position as of December 31, 2023

15.01.24GlobeNewswireGENFIT Announces 2024 Financial Calendar

11.01.24GlobeNewswireGENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

08.12.23GlobeNewswireGENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

07.12.23GlobeNewswireIpsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

06.12.23GlobeNewswireGENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials

16.11.23GlobeNewswireGENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

13.11.23GlobeNewswireGENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

09.11.23GlobeNewswireGENFIT Reports Third Quarter 2023 Financial Information

02.11.23GlobeNewswireGENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023

26.09.23GlobeNewswireGENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology

20.09.23GlobeNewswireGENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update

05.09.23GlobeNewswireGENFIT to Participate in Upcoming Investor Conferences

10.08.23GlobeNewswireGENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications

12.07.23GlobeNewswireGENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

30.06.23GlobeNewswireIpsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

07.06.23GlobeNewswireGENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023

GenfitAct. News

GenfitAct. News: auf dieser Seite finden Sie alle GenfitAct. News und Nachrichten zur GenfitAct. Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch GenfitAct. News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um GenfitAct. News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.